Ensysce reports Q3 net income of $0.7M; awarded $14M NIH grant for PF614-MPAR

Ensysce Biosciences, Inc.

2024-Q3 EPS reported -$0.57 revenue$3,906,372

Net income of $0.7M vs net loss of $2.7M in Q3 2023; driven by $3.4M in federal grant revenue.
Cash & equivalents $4.2M at Sept 30, 2024, up from $1.1M at Dec 31, 2023; $8.5M raised in equity financings.
Awarded $14M multi-year NIH grant for PF614-MPAR; second Phase 1b trial initiated.
Pivotal PF614 Phase 3 protocol submitted to FDA; feedback expected by end of November.
Stockholders' equity $6.6M, compliant with Nasdaq $2.5M listing requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.